Respiratory infections in HIV-infected adults: Epidemiology, clinical features, diagnosis and treatment

Current Opinion in Pulmonary Medicine

Volumn 19, Issue 3, 2013, Pages 238-243

  Capocci, Santino ^a   Lipman, Marc ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

HIV infection; Influenza; Lung; Pneumococcal disease; Pneumocystis

Indexed keywords

BETA 1,3 GLUCAN; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; PENTAMIDINE; PNEUMOCOCCUS VACCINE; PYRIMETHAMINE;

BRONCHIOLITIS OBLITERANS; CHRONIC LUNG DISEASE; CLINICAL FEATURE; COMMUNICABLE DISEASE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTIOUS COMPLICATION; MYCOBACTERIOSIS; NON COMMUNICABLE DISEASE; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL VACCINATION; PNEUMOCYSTIS PNEUMONIA; RESPIRATORY TRACT INFECTION; REVIEW; SEROTYPE; SMALL AIRWAY DISEASE; UNSPECIFIED SIDE EFFECT; VACCINATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; BETA-GLUCANS; HIV INFECTIONS; HUMANS; LUNG DISEASES; PNEUMOCOCCAL INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 84878114906     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32835f1b5c     Document Type: Review

References (42)

1. Buchacz K, Baker RK, Palella FJ, et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010; 24:1549- 1559.
2. Grabar S, Lanoy E, Allavena C, et al. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 2008; 9:246-256.
3. Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDSdefining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55:262- 270.
4. Louie JK, Hsu LC, Osmond DH, et al. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis 2002; 186:1023-1027.
5. Grubb JR, Moorman AC, Baker RK, Masur H. The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS 2006; 20:1095-1107.
6. Drummond MB, Kirk GD, Astemborski J, et al. Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users. Int J Chron Obstruct Pulmon Dis 2011; 6:89-95.
7. Crothers K, Huang L, Goulet JL, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 2011; 183:388-395.
8. Morris A, Crothers K, Beck JM, Huang L, American Thoracic Society Committee on HIV Pulmonary Disease. An official ATS workshop report: emerging issues and current controversies in HIV-associated pulmonary diseases. Proc Am Thorac Soc 2011; 8:17-26.
9. Health Protection Agency. HIV in the United Kingdom: 2012 report. London: Health Protection Services, Colindale; November 2012.
10. British HIV Association. UK National Guidelines for HIV testing. London. [Accessed 23 November 2012]. Available from http://www.bhiva.org/HIV Testing2008.aspx.
11. Søgaard OS, Lohse N, Østergaard L, et al. Morbidity and risk of subsequent diagnosis of HIV: a population based case control study identifying indicator diseases for HIV infection. PLoS One 2012; 7:e32538.
12. Ferrand RA, Desai SR, Hopkins C, et al. Chronic lung disease in adolescents with delayed diagnosis of vertically acquired HIV infection. Clin Infect Dis 2012; 55:145-152.
13. Jeena PM, Coovadia HM, Thula SA, et al. Persistent and chronic lung disease in HIV-1 infected and uninfected African children. AIDS 1998; 12:1185- 1193.
14. Sharland M, Gibb M, Holland F. Respiratory morbidity from lymphocytic interstitial pneumonitis (LIP) in vertically acquired HIV infection. Arch Dis Child 1997; 76:334-336.
15. Heffernan RT, Barrett NL, Gallagher KM, et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005; 191:2038-2045.
16. Nuorti JP, Butler JC, Gelling L, et al. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000; 132:182-190.
17. Gilks CF, Ojoo SA, Ojoo JC, et al. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 1996; 347:718-723.
18. Chapter 25: Pneumococcal. In: Salisbury D, Ramsay M, Noakes K, editors. Immunisation against infectious disease (The Green Book). London: The Stationery Office; 2012. pp. 295-312. [Accessed 19 November 2012]
19. Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccin Immunother 2012; 8:161-173.
20. Geretti AM, Brook G, Cameron C, et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008; 9:795-848.
21. French N, Nakiyingi J, Carpenter LM, et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106-2111.
22. Pedersen RH, Lohse N, Østergaard L, Søgaard OS. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med 2011; 12:323-333.
23. Rodriguez-Barradas MC, Goulet J, Brown S, et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis 2008; 46:1093-1100.
24. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812- 822.
25. Rozenbaum MH, van Hoek AJ, Fleming D, et al. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ 2012; 345:e6879.
26. Burgos J, Peñ aranda M, Payeras A, et al. Invasive pneumococcal disease in HIV-infected adults: clinical changes after the introduction of the pneumococcal conjugate vaccine in children. J Acquir Immune Defic Syndr 2012; 59:31-38.
27. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-2051.
28. Cohen C, Simonsen L, Sample J, et al. Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of America. Clin Infect Dis 2012; 55:996-1003.
29. Chapter 19: Influenza. In: Salisbury D, Ramsay M, Noakes K, editors. Immunisation against infectious disease (The Green Book). London: The Stationery Office; 2012. pp. 185-200. [Accessed November 2012]
30. Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis 2012; 206:1250-1259.
31. Nelson M, Dockrell D, Edwards S, et al. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med 2011; 12 (Suppl.):21-140.
32. Kaplan JE, Benson C, Holmes KH, et al., HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207.
33. Mocroft A, Reiss P, Kirk O, et al. Is it safe to discontinue primary Pneumocystis jirovecii pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count < 200 cells/microL? Clin Infect Dis 2010; 51:611-619.
34. Cheng CY, Chen MY, Hsieh SM, et al. Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 2010; 10:126.
35. + T-cell count < 200 cells/microl when viral replication is suppressed. AIDS 2007; 21:1711-1715.
36. Soriano V, Dona C, Rodríguez-Rosado R, et al. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2000; 14:383-386.
37. Costiniuk CT, Fergusson DA, Doucette S, Angel JB. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count < 200 cells/ml and virologic suppression: a systematic review. PLoS One 2011; 6:e28570.
38. Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1,3-b-Dglucan for Pneumocystis jirovecii pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol 2012; 50:7-15.
39. Sax PE, Komarow L, Finkelman MA, et al. Blood (1!3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis 2011; 53:197-202.
40. Green MR. A modicum of caution for blood (1!3)-b-D-glucan testing for Pneumocystis jirovecii in HIV-infected patients. Clin Infect Dis 2011; 53:1039-1040.
41. Koga M, Koibuchi T, Kikuchi T, et al. Kinetics of serum b-D-glucan after Pneumocystis pneumonia treatment in patients with AIDS. Int Med 2011; 50:1397-1401.
42. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4:e5575.